For decades, sickle cell disease has been managed rather than repaired. Doctors could reduce pain crises, prevent infections, support damaged organs, and—when a suitable donor could be found—replace a patient’s blood-forming system with a stem-cell transplant. But the inherited change at the heart of the disease remained.
That began to change in late 2023, when regulators in the United States and the United Kingdom authorized the first medicines to use CRISPR gene editing in people. One of them, exagamglogene autotemcel—sold in the United States under the name Casgevy—was approved for certain patients with sickle cell disease. It was a milestone not because CRISPR suddenly became simple, but because a powerful molecular tool had been translated into a treatment made from a patient’s own cells.
The achievement also offers a more realistic picture of medical gene editing. Casgevy is not a pill, a one-time injection, or a universal cure. It is an intensive procedure involving cell collection, laboratory editing, chemotherapy, and reinfusion. Yet for people whose lives have been shaped by repeated episodes of severe pain and hospitalization, the possibility of long-term relief is a profound advance.
Why sickle cell disease is so damaging
Sickle cell disease is caused by inherited changes in the HBB gene, which helps cells produce hemoglobin—the protein that carries oxygen. In the most familiar form of the disease, abnormal hemoglobin can cause red blood cells to become rigid and take on a curved, sickle-like shape.
Healthy red blood cells are flexible enough to pass through small blood vessels. Sickle-shaped cells can block that circulation, causing episodes called vaso-occlusive crises. These episodes can produce severe pain and may damage the lungs, kidneys, bones, eyes, brain, and other organs over time. The misshapen cells also break down sooner than normal red blood cells, contributing to chronic anemia.
The disease is inherited and occurs worldwide, although it is particularly common in populations with ancestry from sub-Saharan Africa, parts of the Middle East, South Asia, the Caribbean, and Latin America. Its global burden is shaped not only by biology but also by unequal access to diagnosis, specialist care, pain treatment, blood transfusions, and potentially curative therapies.
One of the body’s natural ways to reduce the problem had been visible for years. Before birth and during early infancy, people make a form of hemoglobin called fetal hemoglobin, or HbF. HbF does not participate in the same sickling process. As a child grows, a regulatory protein called BCL11A helps switch fetal hemoglobin production down.
That suggested an alternative to correcting the original HBB mutation directly: reactivate the body’s fetal-hemoglobin program.
Editing a switch instead of replacing the whole gene
Casgevy uses CRISPR-Cas9 to edit a regulatory region connected to the BCL11A gene. The goal is to reduce BCL11A activity in developing red blood cells, allowing them to produce more HbF. The treatment does not rewrite every cell in the body, and it does not directly repair the sickle hemoglobin gene. Instead, it edits blood-forming stem cells outside the body so that their descendants can make red blood cells with a greater supply of fetal hemoglobin.
The process begins with the patient’s own hematopoietic stem cells. Doctors mobilize those cells from the bone marrow into the bloodstream and collect them through a procedure similar to a specialized blood donation. The cells are then sent to a laboratory, where CRISPR-Cas9 is used to make the intended edit.
While that work is taking place, the patient receives conditioning chemotherapy. This clears space in the bone marrow so the edited cells can establish themselves. The modified cells are then infused back into the patient. If they engraft successfully, they can continue producing blood cells for years.
That sequence explains both the treatment’s promise and its difficulty. The editing is performed on the patient’s own cells, which avoids the need to find a genetically matched donor. But the patient still has to undergo a demanding transplant-like process, including chemotherapy and a prolonged period of recovery while the new blood-forming system takes hold.
What the clinical evidence showed
The evidence that supported the U.S. approval came from a clinical study of patients with sickle cell disease who had a history of serious vaso-occlusive events. The key question was not whether the edited cells could be detected, but whether patients experienced a meaningful reduction in the crises that dominate severe disease.
In the FDA’s review, 29 of 31 evaluable patients achieved freedom from severe vaso-occlusive crises for at least 12 consecutive months. The agency also reported that all 31 evaluable patients avoided hospitalization for vaso-occlusive crises during that same period. These results were based on a relatively small study group, but the effect was substantial enough to establish a new treatment option for eligible patients aged 12 and older.
The early results also showed that the edited cells could engraft and produce blood cells with increased fetal hemoglobin. In practical terms, the treatment aims to change the blood-making system so that sickling becomes far less likely, rather than treating each crisis after it occurs.
Researchers published longer-term follow-up in the New England Journal of Medicine as the program developed. The results strengthened the case that fetal-hemoglobin reactivation can produce durable clinical benefit, while also underscoring the need for continued observation. Gene-editing studies must follow participants for years because some possible risks—particularly rare effects from unintended editing or later changes in blood-cell behavior—cannot be ruled out by a short trial.
A landmark with serious practical limits
Calling Casgevy a cure requires care. Some treated patients have remained free of severe crises for the follow-up period reported to regulators, but scientists are still learning how durable the benefit will be across decades. The treatment does not reverse organ damage that occurred before therapy, and it does not remove every medical consequence of sickle cell disease overnight.
The conditioning chemotherapy is another important consideration. It can cause infertility and carries risks such as infection, low blood-cell counts, nausea, and other complications. Patients need highly specialized centers capable of collecting, handling, editing, and reinfusing stem cells, as well as monitoring recovery.
Cost and geography may prove just as consequential as biology. A medicine that requires a sophisticated cell-processing chain cannot reach patients unless health systems can pay for it and deliver the supporting care. Many people with sickle cell disease live in regions where even established treatments remain difficult to obtain. The first CRISPR approvals therefore create a dual challenge: prove that the therapy remains safe and effective over the long term, and build fairer ways for eligible patients to receive it.
There is also a distinction between Casgevy and another therapy approved by the FDA at the same time. Lyfgenia uses a different gene-therapy strategy to introduce genetic instructions into a patient’s blood-forming stem cells. Both treatments represent major advances, but they are not interchangeable versions of one product. Their risks, manufacturing methods, evidence, and long-term monitoring requirements differ.
Why this matters beyond sickle cell disease
The importance of Casgevy extends beyond its first disease target. It demonstrates that CRISPR can move through the entire medical pipeline: identifying a useful biological switch, editing a patient’s cells under controlled conditions, returning those cells to the body, and measuring whether the result improves daily health.
That experience will inform research into other inherited blood disorders, including beta thalassemia, which shares some of the same biology. It may also help scientists design future therapies for diseases in which a small, well-chosen genetic change can restore a missing function or redirect a harmful process.
Still, the lesson is not that gene editing has become universally ready. Each disease presents a different target, and editing blood-forming stem cells is more accessible than editing many organs deep inside the body. The safety of the edit, the delivery method, the conditioning regimen, and the manufacturing process all have to work together.
For patients with severe sickle cell disease, however, the first CRISPR approval marks a real shift in what medicine can offer. A condition once approached mainly through lifelong management now has a treatment designed to alter the source of the problem’s blood-cell biology. The procedure is demanding, access remains uneven, and long-term questions are still open. But the central achievement is already clear: a genetic instruction that once seemed fixed can now be approached as something medicine may be able to change.
